With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Join Drs. Rosenson, Lüscher, and Deanfield as they discuss the potential clinical impact of AIM-HIGH and the latest CETP-inhibitor clinical trials from a global perspective.
Novel oral anticoagulants hold the promise of simplifying the treatment of acute and recurrent VTE; Drs. Turpie, Agnelli, and Cohen discuss recent findings.
Drs. Fox, Califf, Connolly, and Patel review key clinical-trial data of novel oral anticoagulants and use real-world case scenarios to discuss strategies on how to best manage patients with AF and other comorbidities.
For more accurate diagnosis and cost savings too — when contrast-enhanced echocardiography makes sense. Drs. Garcia, Castello, and Main cover the bases and illustrate with cases.
Prostanoids are the most potent therapies for PAH, yet they are underused. Drs. Waxman, Frantz, and Chakinala discuss barriers to their use and when and how to use them.
Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP-inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.
Join Dr. Nicholls as he discusses the clinical significance of HDL-C for residual cardiovascular risk and whether HDL functionality would be a better predictor of therapeutic success. And DISCUSS this topic with Dr. Nicholls on Medscape Discuss.
PARTNER, RIFLE, TWENTE, transcatheter valves, novel DES, and renal denervation — Drs. Worthley and Meredith give their take on the hot topics for the interventionalist.